TGFβRI-IN-3

TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology[1].

Product Specifications

CAS Number

[2763602-67-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

TGF-β Receptor

Type

Reference compound

Related Pathways

TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tgfβri-in-3.html

Purity

98.21

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CS(C1=CC=C(C=C1)C2=CC=C3C(NC4=CC=NC(C5=CC(C)=CC=C5)=C4)=CC=NC3=C2)(=O)=O

Molecular Formula

C28H23N3O2S

Molecular Weight

465.57

Precautions

H302, H315, H319

References & Citations

[1]Kharbanda A, et al. Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology [published online ahead of print, 2021 Aug 12]. Eur J Med Chem. 2021;225:113763.